Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 227 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Genetic Expression Clear all

Conditions: Breast Cancer
Interventions: tamoxifen citrate, gene expression analysis, protein expression analysis, immunoenzyme technique, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions: sorafenib tosylate, microarray analysis, immunohistochemistry staining method, gene expression analysis, needle biopsy, therapeutic conventional surgery, laboratory biomarker analysis, western blotting, RNA analysis; Drug · Genetic · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Kidney Cancer
Interventions: sunitinib malate, gene expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery; Drug · Genetic · Other + 1 more
Lead sponsor: Harry Drabkin; Other
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cancer
Interventions: RNA sequencing, Transcriptome analysis, target drug with the score above 0,1, target drug with the score equal or below 0,1, non-target drug, palliative care; Other · Drug
Lead sponsor: OmicsWay Corp.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Walnut, California

Conditions: Bladder Cancer, Urethral Cancer
Interventions: Recombinant Interferon Alfa; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pregnancy, Cesarean Delivery
Interventions: Manual removal, Expressed removal; Behavioral · Procedure
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Adenocarcinoma Pancreas
Interventions: Surgery, Genetic Expression, Chemotherapy; Procedure · Genetic · Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cardiovascular Disease
Interventions: Decoding Your Diet; Genetic
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lung Cancer
Interventions: gold sodium thiomalate, gene expression analysis, fluorine F 18 fluorothymidine, mass spectrometry, pharmacological study; Drug · Genetic · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD
Interventions: Not listed
Lead sponsor: CardioDx; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sarcoma
Interventions: DNA analysis, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis; Genetic · Other
Lead sponsor: University of Arizona; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Leukemia
Interventions: dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Peripheral Neuropathic Pain, Neurotoxicity, Cancer
Interventions: Not listed
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ocular Inflammatory Disease, Uveitis
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 6 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Cancer, Melanoma (Skin)
Interventions: recombinant interleukin-7, gene expression analysis, polymerase chain reaction, protein expression analysis, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study; Biological · Genetic · Other
Lead sponsor: Cytheris SA; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain
Interventions: Valdecoxib, COX Inhibitor; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 7 Years to 35 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Central Nervous System Embryonal Neoplasm
Interventions: Not listed
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 2 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more

Conditions: Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique; Genetic · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 1 Year to 55 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1975 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms
Interventions: Fine needle aspiration biopsy; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atopic Asthma, Healthy
Interventions: House Dust Mite, Diluent; Biological
Lead sponsor: John Sundy; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: Positive for SARS-CoV-2 infection; Diagnostic Test
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Not listed
Lead sponsor: Temple University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 1,066 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 3
States / cities: Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Search by objective public record fields.

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery

Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

Assessment of Candidate Protein Expression in Breast Cancer Specimens

Manual and Expressed Placental Removal at Cesarean Delivery and Its Effects on Various Cardiac Indices

Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas

Decoding Your Diet (DYD)

Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial

Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage

Differences in Genes and Proteins in Active and Controlled Uveitis

Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Validation of a Molecular Prognostic Test for Eye Melanoma

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge

COVID-19 on Placental Gene Expression and Pathology

Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations